BROADCASTS.com

Elle Russ chats with Dr. Dale Bredesen, MD - he received his undergraduate degree from Caltech and his medical degree from Duke.\xa0 He served as Resident and Chief Resident in Neurology at UCSF, then was postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner.\xa0 He was a faculty member at UCLA from 1989-1994, then was recruited by the Burnham Institute to direct the Program on Aging.\xa0 In 1998 he became the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as the Director of the Easton Center for Alzheimer\u2019s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer\u2019s disease and other neurodegenerative conditions, leading to the publication of over 220 research papers. He established the ADDN (Alzheimer\u2019s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer\u2019s disease.\xa0 He and his group developed a new approach to the treatment of Alzheimer\u2019s disease, and this approach led to the discovery of subtypes of Alzheimer\u2019s disease, followed by the first description of reversal of symptoms in patients with MCI and Alzheimer\u2019s disease, with the ReCODE (reversal of cognitive decline) protocol, published in 2014, 2016, and 2018.\xa0 Dr. Bredesen is the author of the New York Times best seller, The End of Alzheimer\u2019s, and the newly released, The End of Alzheimer\u2019s Program.